1 Department of Pediatrics, Division of Infectious Diseases, University of Tennessee, Memphis, LeBonheur Children's Medical Center, Memphis, Tennessee 38103
To the Editor.
I read with interest the editorial by Abramson and Givner on the use of tetracycline for suspected Rocky Mountain spotted fever (RMSF) in children younger than 9 years of age.1 Their discussion of the relative risks and benefits of tetracycline or chloramphenicol for RMSF and their conclusion that the contraindication of tetracycline (due to its risk of teeth-staining) in all children younger than 9 years old does not seem warranted is relevant to another tick-borne infection, tularemia.2